Revolution Medicines officer sells 92K shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Revolution Medicines, Inc. (RVMD) reported that senior advisor to the CEO Stephen Michael Kelsey exercised stock options for a total of 92,531 shares of Common Stock on September 11, 2026, at exercise prices of $42.45 and $40.74 per share and sold 92,531 shares in multiple transactions at prices around $200 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026, and reported sale prices reflect weighted average prices for trades executed within specified intraday ranges.
Insider Trade Summary 10b5-1
Exercise and Sale: 92,531 shares ($14.87M approx. pre-tax spread)
Exercise and Sale
12 txns
Insider
Kelsey Stephen Michael
Role
See Remarks
Sold
92,531 shs ($18.72M)
Approx. gross sale proceeds
$18.72M
Approx. exercise cost
$3.86M
Approx. pre-tax spread
$14.87M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F11 | 52,500 | $42.45 | $2.23M |
| Exercise | Stock Option (Right to Buy) F1, F12 | 40,031 | $40.74 | $1.63M |
| Exercise | Common Stock F1 | 52,500 | $42.45 | $2.23M |
| Exercise | Common Stock F1 | 40,031 | $40.74 | $1.63M |
| Sale | Common Stock F1, F2 | 800 | $198.5502 | $159K |
| Sale | Common Stock F1, F3 | 11,833 | $200.1145 | $2.37M |
| Sale | Common Stock F1, F4 | 13,368 | $200.7769 | $2.68M |
| Sale | Common Stock F1, F5 | 21,447 | $201.7507 | $4.33M |
| Sale | Common Stock F1, F6 | 18,869 | $203.0606 | $3.83M |
| Sale | Common Stock F1, F7 | 17,949 | $203.8726 | $3.66M |
| Sale | Common Stock F1, F8 | 4,995 | $204.8427 | $1.02M |
| Sale | Common Stock F1, F9, F10 | 3,270 | $205.8075 | $673K |
Holdings After Transaction:
Stock Option (Right to Buy) — 88,069 contracts (Direct);
Common Stock — 291,876 shares (Direct)
Footnotes (12)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026.
- F2. The transaction was executed in multiple trades at prices ranging from $198.35 to $198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. The transaction was executed in multiple trades at prices ranging from $199.36 to $200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4. The transaction was executed in multiple trades at prices ranging from $200.36 to $201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5. The transaction was executed in multiple trades at prices ranging from $201.39 to $202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6. The transaction was executed in multiple trades at prices ranging from $202.41 to $203.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7. The transaction was executed in multiple trades at prices ranging from $203.45 to $204.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8. The transaction was executed in multiple trades at prices ranging from $204.46 to $205.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9. The transaction was executed in multiple trades at prices ranging from $205.57 to $206.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F10. Includes 76,251 restricted stock units.
- F11. Fully vested.
- F12. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Key Figures
Options Exercised: 92,531 shares
Shares Sold: 92,531 shares
Option Exercise Price 1: $42.45 per share
+5 more
8 metrics
Options Exercised
92,531 shares
Stock options exercised into Common Stock on September 11, 2026
Shares Sold
92,531 shares
Common Stock sales on September 11, 2026
Option Exercise Price 1
$42.45 per share
Exercise of 52,500 Stock Option shares expiring March 4, 2031
Option Exercise Price 2
$40.74 per share
Exercise of 40,031 Stock Option shares expiring March 1, 2035
Sale Price Range
$198.35–$206.05 per share
Weighted-average priced sales executed in multiple trades on September 11, 2026
Restricted Stock Units
76,251 units
Footnote states reported holdings include 76,251 restricted stock units
10b5-1 Plan Adoption Date
June 12, 2026
Rule 10b5-1 trading plan under which the transactions were made
Vesting Commencement Date
March 1, 2025
Start date for monthly vesting of the 2035-expiring stock option
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, restricted stock units, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported in Column 4 above reflects the weighted average sale price"
restricted stock units financial
"Includes 76,251 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"shares initially subject to the option will vest on each monthly anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did RVMD insider Stephen Michael Kelsey report on this Form 4?
Stephen Michael Kelsey, a senior advisor to the CEO of RVMD, reported exercising stock options for 92,531 shares of Common Stock and selling 92,531 shares on September 11, 2026, in a series of transactions around $200 per share.
How many RVMD options did Kelsey exercise and at what prices?
Kelsey exercised options covering 92,531 shares of RVMD Common Stock on September 11, 2026, including 52,500 shares at $42.45 per share and 40,031 shares at $40.74 per share, converting these derivative securities into Common Stock.
Were Kelsey’s RVMD trades made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026, indicating these sales were pre-arranged under that plan.
What information is given about Kelsey’s remaining RVMD equity awards?
A footnote states that Kelsey’s reported holdings include 76,251 restricted stock units. Another footnote notes that one option reported as exercised was fully vested, while a separate option vests monthly over four years starting March 1, 2025.
What is Kelsey’s role at Revolution Medicines (RVMD)?
Kelsey is identified as an officer of Revolution Medicines with the title given by remarks as Senior Advisor to the Chief Executive Officer, and he is the reporting person for the transactions disclosed in this Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
